Back

Understanding the underpinning of hypertriglyceridemia as a risk factor for atherosclerosis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiology of ischaemic heart disease Pathophysiology and Mechanisms ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Matilde Ferreira

Hospital Funchal, Funchal (Portugal)

7 More presentations in this session

Presentation thumbnail
Unlocking the inflammatory 'code' in multivessel coronary disease: pathological network mediated by the PCSK9-NLRP3 axis and a novel microcirculatory dysfunction prediction model
Professor C. Liu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Adipocytokines and risk of ischaemic events in acute coronary syndromes: an age-dependent relationship
Doctor F. Bruno (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Plasma lysozyme as surrogate biomarker for detection of coronary artery disease in patients without Standard Modifiable Cardiovascular Risk Factors (SMuRFless)
Doctor S. Fathieh (London, GB)
Abstract Slides Video
Presentation thumbnail
Xanthosine alleviates myocardial ischemia-reperfusion injury through attenuation of cardiomyocyte ferroptosis
Doctor Y. Xu (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Pathology of medial calcification in coronary arteries
Doctor N. Nakamura (Isehara, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology of ischaemic heart disease

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
How genetic variants and excess of weight influence risk of coronary artery disease
thumbnail
Congress Presentation
Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome
thumbnail
Congress Presentation
Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and lipid-lowering therapy intensity in cardiovascular disease patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources